Nektar Therapeutics Maps Key REZPEG Data Milestones for 2027 and 2028

Nektar Therapeutics (NASDAQ:NKTR) expects the first results from its late-stage atopic dermatitis program for rezpegaldesleukin, or REZPEG, around the summer of 2028, with additional data on how long patients maintain their response after stopping treatment due in early 2027.

Chief Research and Development Officer Jonathan Zalevsky outlined the company’s development plans at the UBS Global Biopharma Conference. He said Nektar has launched three Phase 3 studies in atopic dermatitis and plans to begin a registrational study in alopecia areata in December.

REZPEG is designed to selectively stimulate regulatory T cells, which help regulate immune responses. Zalevsky said earlier studies suggested that some patients maintained or improved their responses after treatment ended, though he cautioned that it was too early to discuss whether the drug could cure disease.

Off-treatment data due in early 2027

Nektar expects first-quarter 2027 data from an off-treatment observation period in a Phase 2 atopic dermatitis study. The roughly 400-patient trial included a maintenance period through week 52, followed by a year of observation without treatment.

Zalevsky said 125 patients entered the observation period after completing maintenance: 110 had received REZPEG and 15 had received placebo. Unlike randomized withdrawal studies that use sham injections, patients received no intervention during the observation period, he said.

As a benchmark, Zalevsky cited a Dupixent placebo-withdrawal study in which approximately half of patients maintained an EASI75 response—a measure of at least 75% improvement in eczema severity—over nine months. He said a similar level of durability at 12 months would represent success for REZPEG. The studies differ in duration and design and were not described as a head-to-head comparison.

Zalevsky said sustained responses could support infrequent dosing or treatment breaks, although those approaches remain to be established.

Phase 3 studies target different patient groups

The three ZENITH-AD studies will each enroll approximately 510 patients aged 12 and older with moderate-to-severe atopic dermatitis, according to Zalevsky. They are designed to evaluate REZPEG across different treatment settings:

  • AD1: REZPEG alone in patients who have not previously received a biologic or JAK inhibitor.
  • AD2: REZPEG with topical corticosteroids in patients both with and without prior biologic or JAK inhibitor treatment.
  • AD3: REZPEG alone in patients previously treated with a biologic and/or JAK inhibitor.

Zalevsky expects top-line induction results from AD1 around the summer of 2028. Nektar has not provided specific timing for AD2 and AD3, but he said their results could follow relatively close to AD1.

He argued that REZPEG’s mechanism could distinguish it from treatments that block inflammatory pathways, including products targeting IL-4 and IL-13. The company also wants to demonstrate efficacy in patients who have previously received other systemic treatments.

Alopecia and vitiligo plans

The planned alopecia areata registrational study will enroll about 850 patients aged 12 and older with severe to very severe disease, Zalevsky said. Participants will receive REZPEG twice monthly for 52 weeks, with the primary endpoint measuring the proportion who reach a SALT score of 20 or better, a measure of scalp hair loss.

In the Phase 2 study, nearly 30% of patients reached that benchmark, he said. Among patients who regrew hair and were followed for six months after stopping treatment, 63% retained at least some of their regrowth, while some continued to grow hair, according to Zalevsky.

Nektar also plans a roughly 30-patient study of REZPEG in vitiligo. Zalevsky said the goal is to obtain data before the first Phase 3 atopic dermatitis readout in summer 2028.

The company is developing preclinical TNFR2 assets intended to help maintain regulatory T-cell function. Zalevsky said Nektar expects some increase in research and development spending as it runs the late-stage studies and is financed through the third quarter of 2028.

About Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.